McAnally Heath
Northern Anesthesia & Pain Medicine, LLC, 10928 Eagle River Rd #240, Eagle River, AK 99577 USA.
Department of Anesthesiology and Pain Medicine, University of Washington, Box 356540, Seattle, WA 98195-6540 USA.
Perioper Med (Lond). 2017 Nov 22;6:19. doi: 10.1186/s13741-017-0079-y. eCollection 2017.
The practice of chronic opioid prescription for chronic non-cancer pain has come under considerable scrutiny within the past several years as mounting evidence reveals a generally unfavorable risk to benefit ratio and the nation reels from the grim mortality statistics associated with the opioid epidemic. Patients struggling with chronic pain tend to use opioids and also seek out operative intervention for their complaints, which combination may be leading to increased postoperative "acute-on-chronic" pain and fueling worsened chronic pain and opioid dependence. Besides worsened postoperative pain, a growing body of literature, reviewed herein, indicates that preoperative opioid use is associated with significantly worsened surgical outcomes, and severely increased financial drain on an already severely overburdened healthcare budget. Conversely, there is evidence that preoperative opioid reduction may result in substantial improvements in outcome. In the era of accountable care, efforts such as the Enhanced Recovery After Surgery (ERAS) protocol have been introduced in an attempt to standardize and facilitate evidence-based perioperative interventions to optimize surgical outcomes. We propose that addressing preoperative opioid reduction as part of a targeted optimization approach for chronic pain patients seeking surgery is not only logical but mandatory given the stakes involved. Simple opioid reduction/abstinence however is not likely to occur in the absence of provision of viable and palatable alternatives to managing pain, which will require a strong focus upon reducing pain catastrophization and bolstering self-efficacy and resilience. In response to a call from our surgical community toward that end, we have developed a simple and easy-to-implement outpatient preoperative optimization program focusing on gentle opioid weaning/elimination as well as a few other high-yield areas of intervention, requiring a minimum of resources.
在过去几年中,慢性非癌性疼痛的长期阿片类药物处方行为受到了相当多的审视,因为越来越多的证据表明其风险效益比总体不利,而且美国正深受与阿片类药物流行相关的严峻死亡率统计数据的影响。患有慢性疼痛的患者倾向于使用阿片类药物,并且还会因自身病痛寻求手术干预,这种情况可能导致术后“慢性疼痛急性发作”增加,并加剧慢性疼痛和阿片类药物依赖。除了术后疼痛加剧外,本文回顾的越来越多的文献表明,术前使用阿片类药物与手术结果显著恶化以及在本就负担过重的医疗保健预算上造成严重的财务负担增加有关。相反,有证据表明术前减少阿片类药物使用可能会使结果得到实质性改善。在责任医疗时代,诸如术后加速康复(ERAS)方案等措施已被引入,试图规范并促进基于证据的围手术期干预措施,以优化手术结果。我们认为,鉴于所涉及的利害关系,将术前减少阿片类药物使用作为寻求手术的慢性疼痛患者有针对性的优化方法的一部分不仅合乎逻辑,而且是必要的。然而,在没有提供可行且易于接受的疼痛管理替代方案的情况下,单纯减少/停用阿片类药物不太可能实现,这将需要高度关注减少疼痛灾难化以及增强自我效能感和恢复力。为响应我们外科界为此发出的呼吁,我们制定了一个简单且易于实施的门诊术前优化方案,重点是温和地减少/停用阿片类药物以及其他一些高收益的干预领域,所需资源最少。